Document is current
Any future updates will be listed below
-
Authors
Jony, Md Jobair Hossen
Ranjbar, Sheyda
Prajapati, Rama
Eslami, Seyyed Majid
Zhen, Zixuan
Darji, Mittal
Zhu, Xueli
Lu, Xiuling https://orcid.org/0000-0002-1961-8156
-
Funding
Funding for this research was provided by:
National Cancer Institute (R41CA239989, R44CA239989)
American Cancer Society (RSG-15-011-01-CDD)
- License Information
-
More Information
Article History
Received: 1 July 2025
Accepted: 12 August 2025
First Online: 25 August 2025
Declarations
:
: Dr. Xiuling Lu is an inventor on intellectual property licensed to Nami Therapeutics Corp for developing silica nanoparticle-based radiopharmaceuticals. Dr. Xiuling Lu owns equity. It is important to note that the analysis and interpretation in this study were without any influence from the potential financial gains. The authors affirm that the conclusions drawn and the information provided in this paper are based on scientific evidence.
